Hexarelin (5mg x 10 Vials) & Mod GRF 1 29 (CJC1295 no DAC) (5mg x 10 Vials)

Derma Filler Ltd

Research peptide combination

Growth hormone secretagogue and GHRH analogue peptide vials for laboratory research

Sold as a research chemical / laboratory reagent, typically labelled “for research use only, not for human consumption” by major peptide suppliers
Not authorised as a medicinal product by the MHRA, EMA, FDA or other medicines regulators
Use of growth Hormone Axis peptides in competitive sport may be prohibited under anti Doping regulations; laboratories and institutions are responsible for ensuring regulatory compliance in their jurisdiction

Sold as a research chemical / laboratory reagent, typically labelled “for research use only, not for human consumption” by major peptide suppliers
Not authorised as a medicinal product by the MHRA, EMA, FDA or other medicines regulators
Use of growth Hormone Axis peptides in competitive sport may be prohibited under anti Doping regulations; laboratories and institutions are responsible for ensuring regulatory compliance in their jurisdiction

Growth hormone secretagogue and GHRH analogue peptide vials for laboratory research

Description

This product is a laboratory research bundle containing two separate lyophilised peptide preparations: Hexarelin 5 mg per vial (10 vials) and Mod GRF 1-29, also known as CJC-1295 no DAC, 5 mg per vial (10 vials). In total, the set provides 20 sterile, stoppered glass vials of freeze-dried peptide powder intended exclusively for in vitro and pre-clinical research on growth-hormone secretagogue pathways and growth-hormone-releasing hormone (GHRH) receptor signalling. Suppliers describe Hexarelin as a synthetic growth hormone-releasing peptide (GHRP) and Mod GRF 1-29 (CJC-1295 no DAC) as a short-acting GHRH analogue. The product is marketed strictly as a research reagent, typically labelled as not for human consumption, injection or veterinary use and not as an approved medicinal product.

Bnefits

Provides two complementary research peptides, Hexarelin and Mod GRF 1-29 (CJC-1295 no DAC), in a single bundle for studies of the growth hormone axis
Each peptide supplied in 5 mg lyophilised form, facilitating precise preparation of a range of experimental concentrations in the laboratory
Total of 20 vials (10 Hexarelin, 10 Mod GRF 1-29) aids multi-arm or repeated experiments without frequent reordering
Lyophilised (freeze-dried) powder format is suitable for extended storage stability under appropriate conditions
Suppliers advertise high peptide purity (commonly ≥99% by HPLC) for research applications
Both compounds are widely referenced in the scientific literature as tools for investigating growth-hormone secretagogue receptors and GHRH receptors
Marketed specifically for research use only, helping to delineate non-clinical from clinical applications

Indications

Intended use: in vitro and pre-clinical laboratory research on growth hormone secretagogue receptor (GHSR) signalling and growth hormone-releasing hormone (GHRH) receptor pathways
Model development for studying growth hormone and IGF-1 regulation in cell systems and experimental animals under controlled ethical approval
Mechanistic research into ghrelin-receptor and GHRH-receptor interactions and potential synergistic effects of combined secretagogue and GHRH-analog stimulation
Pharmacology, receptor-binding and pathway-activation studies for educational and research purposes
No approved human or veterinary medical indications; not licensed as a medicine or therapy

Composition

Hexarelin: synthetic growth hormone-releasing peptide belonging to the GHRP / growth hormone secretagogue class; supplied as lyophilised peptide powder, 5 mg per sterile vial (exact amino-acid sequence and peptide purity specification typically provided in the supplier’s technical documentation)
Mod GRF 1-29 (CJC-1295 no DAC): synthetic 29-amino-acid analogue of growth hormone-releasing hormone (GHRH), commonly referred to as CJC-1295 without DAC; supplied as lyophilised peptide powder, 5 mg per sterile vial
Typical research peptide excipients (not specified on the seller’s site but commonly including mannitol or similar bulking agents) may be present to aid lyophilisation and stability
Vials are sterile, crimp-sealed glass vials suitable for laboratory handling and reconstitution in appropriate research-grade diluents

Formulation

Dosage form: lyophilised (freeze-dried) peptide powders in stoppered glass vials
Strength: Hexarelin 5 mg per vial (10 vials) and Mod GRF 1-29 (CJC-1295 no DAC) 5 mg per vial (10 vials)
Intended for reconstitution with a suitable sterile research diluent (e.g., bacteriostatic water or other buffer) in controlled laboratory settings only, following institutional SOPs
Marketed by peptide vendors explicitly as research-use-only reagents and not as finished pharmaceutical products

Packaging

Total of 20 individual glass vials in one bundle: 10 vials containing Hexarelin 5 mg and 10 vials containing Mod GRF 1-29 (CJC-1295 no DAC) 5 mg
Vials supplied with crimped rubber stoppers and protective caps, typically grouped in secondary packaging (box or tray) for transit
Outer packaging includes vendor branding, product identification and standard research-chemical labelling such as “for research use only, not for human consumption” where required

Usage

For professional laboratory and research use only; not for human or veterinary use, injection, ingestion or any form of clinical administration
Handle in accordance with institutional chemical and biological safety procedures, including appropriate personal protective equipment (PPE) and waste disposal protocols
Reconstitution, dilution and experimental use should be performed only by trained personnel in controlled laboratory environments, following local SOPs and the supplier’s technical documentation where provided
Do not use this product to diagnose, treat, cure or prevent any disease in humans or animals
End users should comply with all applicable regulations and ethical guidelines governing the use of research peptides in their jurisdiction

Contraindications

Contraindicated for any form of human or veterinary administration, including injection, ingestion, implantation or topical application
Must not be used by individuals without appropriate laboratory training and access to suitable research facilities and safety equipment
Use is inappropriate in any setting that would contravene local, national or international regulations on unlicensed medicinal products, doping agents or research chemicals
Individuals or entities unable to comply with research-use-only conditions and safe-handling regulations should not purchase or possess this product

Adverse Effects

No approved safety or tolerability profile in humans or animals, as the product is not authorised for clinical use
Potential toxicology, off-target effects and long-term safety are incompletely characterised and remain topics of pre-clinical research
Any accidental exposure (e.g., needle-stick, splash to mucous membranes or skin) should be managed according to institutional incident and occupational-health protocols, and may warrant medical evaluation
Use outside regulated research settings could involve unknown and potentially serious risks

Storage Conditions

Store lyophilised peptide vials in a cool, dry place protected from light; many peptide suppliers recommend refrigerated or frozen storage for optimal long-term stability
Avoid exposure to high temperatures, moisture and direct sunlight during shipping and storage
Maintain vials in their original secondary packaging until use to reduce risk of contamination or light exposure
After any laboratory reconstitution, follow institutional guidelines and the supplier’s technical documentation for short-term storage, and dispose of any unused solution safely once experiments are complete
Keep out of reach of unauthorised personnel and never store alongside medicinal products intended for human or veterinary use

Duration

Not applicable \u2013 this is a laboratory research reagent bundle and is not licensed or recommended for any treatment regimen or clinical use in humans or animals.

Onset

Not clinically characterised; any functional effects are the subject of controlled laboratory experiments only. No therapeutic onset-of-action profile is established or approved for human or veterinary use.